News | October 03, 2012

NIH Awards Grant for Standardization of PET/CT Scanners in Clinical Trials

Clinical Trial NIH NCI PET/CT Systems Standardization

October 3, 2012 — The National Institutes of Health (NIH)/National Cancer Institute (NCI) has awarded a five-year research project grant (R01) to identify harmonized reconstruction parameters for each currently-produced positron emission tomography (PET)/computed tomography (CT) scanner for use in clinical trials. The Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Clinical Trials Network (CTN) will serve as an administrative coordinating body for the Image Reconstruction Harmonization Grant, which was awarded in August to the Universities of Iowa, Pennsylvania, and Washington.

“Lack of standardized images is a large source of variability when using imaging in multi-center clinical trials,” said John J. Sunderland, Ph.D., director of PET imaging at the University of Iowa and the contact principle investigator for the grant. “Our goal with the grant is to identify a set of reconstruction parameters specific to each of the PET/CT scanner models currently in production that will result in images that will have quantitatively identical image properties.”

In standard clinical situations operators are free to reconstruct PET images according to their standard protocols.  However, during a clinical trial, the site will be able to generate harmonized images by simply using the identified clinical-trial specific reconstruction parameters. With the cooperation of scanner manufacturers, who are also actively participating in this project, generating harmonized PET images for use in multi-center clinical trials will be as easy as flipping a switch.

Co-principle investigators for the grant include Paul E. Kinahan, Ph.D., professor of radiology at the University of Washington in Seattle, and Joel S. Karp, Ph.D., professor of radiology at the University of Pennsylvania. Additionally, high-level physicists and engineers from GE, Philips, and Siemens — the three companies that currently manufacture PET/CT scanners — will actively participate in the research as industry co-investigators.

Importantly, this work is being coordinated with related quantitative imaging efforts by other professional organizations, including the NCI’s Quantitative Imaging Network, the American College of Radiology Imaging Network and Radiological Society of North America’s Quantitative Imaging Biomarker Alliance. In addition, there is active involvement by scientists from the National Institute of Standards and Technology, the European Association of Nuclear Medicine and the European Organization of Research and Treatment of Cancer.

“By having the capability to standardize PET/CT scanners among the three manufacturers, we will be in a much better place to harmonize images in clinical trials. This will allow pharmaceutical companies to use imaging more efficiently and effectively in the development of drugs for chemotherapy, brain imaging and more,” noted Michael M. Graham, Ph.D., M.D., director of nuclear medicine at the University of Iowa and co-chair of SNMMI’s CTN.

For more information: www.snmmi.org

Related Content

Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist
Technology | Ventricular Assist Devices (VAD) | September 27, 2019
Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre...
CorWave Presents First Successful In Vivo 60-day Study of Neptune LVAD
News | Ventricular Assist Devices (VAD) | September 12, 2019
CorWave announced successful completion of its first 60-day preclinical study to evaluate its Neptune left ventricular...
Experts Caution Against Catch-all Assumptions About LVADs and Mitral Regurgitation

Paul Tang, M.D., Ph.D., a cardiac surgeon at Michigan Medicine’s Frankel Cardiovascular Center in the OR. Image courtesy of Michigan Medicine.

News | Ventricular Assist Devices (VAD) | August 20, 2019
Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create significant...
FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Overlay Init